All the relevant data?BMJ 2010; 341 doi: https://doi.org/10.1136/bmj.c6487 (Published 16 November 2010) Cite this as: BMJ 2010;341:c6487
- Erick H Turner, assistant professor, Oregon Health and Science University1
- 1Portland VA Medical Center, P3MHDC, 3710 SW US Veterans Hospital Road, Portland, Oregon 97239, USA
I previously worked at the US Food and Drug Administration (FDA) and was the medical officer who reviewed the new drug application for reboxetine.
Eyding and colleagues state, “we are optimistic that we analysed the vast majority or even all” of the relevant data.1 But is such optimism warranted? Because the FDA rejected the reboxetine application for lack of efficacy,2 …